• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, September 5, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Quantifying lower limb muscle weakness in Osteogenesis Imperfecta type IV

Bioengineer by Bioengineer
July 26, 2017
in Biology
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Osteogenesis Imperfecta (OI) is a heritable disorder characterized by increased bone fragility.

In OI Type IV muscle weakness has important functional consequences. Children and adolescents with OI type IV often have restricted mobility despite multidisciplinary treatment with bisphosphonates, intramedullary rodding surgery and rehabilitation.

To date, muscle function, and in particular that of the lower extremity, in OI type IV has not been investigated systematically. A new study in the journal 'Calcified Tissue international' has now assessed upper and lower extremity muscle function in 27 children and adolescents aged 7-21 years with OI type IV, compared with age-and sex-matched controls. The researchers found that the patients, all with a clinical diagnosis of OI type IV and known mutations in the COLIA1 and COLIA2 genes, had:

  • approximately 30% lower-limb peak force and 50% peak power deficits compared to healthy age- and sex-matched controls.
  • at the lower limb level, a 50% lower peak power than age- and sex- matched patients with OI type 1 (the type of OI with the mildest form of bone fragility).
  • normal upper-limb muscle force, but a muscle function deficit at the lower-limb level.

Among the potential determinants of lower-limb muscle function in OI type IV, only fracture history emerged as a significant negative predictor. The number of fractures is likely to explain periods of inactivity which contributes to lower muscle function. Muscle function may also be impaired by a direct effect of collagen type 1 mutations on tendons, ligaments and intramuscular connective tissue, although more studies are needed to clarify this aspect.

The results suggest that lower limb weakness may contribute to limitations in mobility in people with OI Type IV despite multidisciplinary treatment.

###

Reference

Veilleux, LN., Darsaklis, V.B., Montpetit, K. et al. Muscle Function in Osteogenesis Imperfecta Type IV Calcif Tissue Int (2017). doi:10.1007/s00223-017-0287-y

https://link.springer.com/article/10.1007/s00223-017-0287-y

About Calcified Tissue International & Musculoskeletal Research:

Calcified Tissue International & Musculoskeletal Research is a peer-reviewed journal which publishes original preclinical, translational and clinical research, and reviews concerning the structure and function of bone, and other musculoskeletal tissues in living organisms, as well as clinical studies of musculoskeletal disease. It includes studies of cell biology, molecular biology, intracellular signalling, and physiology, as well as research into the hormones, cytokines and other mediators that influence the musculoskeletal system. The journal also publishes clinical studies of relevance to bone disease, mineral metabolism, muscle function, and musculoskeletal interactions.

Editors in Chief: Stuart Ralston and René Rizzoli; Musculoskeletal Research Section Editor: Roger Fielding.

http://link.springer.com/journal/223

About IOF:

The International Osteoporosis Foundation (IOF) is the world's largest nongovernmental organization dedicated to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. IOF members, including committees of scientific researchers as well as 240 patient, medical and research societies in 99 locations, work together to make fracture prevention and healthy mobility a worldwide heath care priority. http://www.iofbonehealth.org / http://www.facebook.com/iofbonehealth @iofbonehealth

Media Contact

L. Misteli
[email protected]
41-229-940-100
@iofbonehealth

http://www.iofbonehealth.org

http://dx.doi.org/10.1007/s00223-017-0287-y

Share12Tweet7Share2ShareShareShare1

Related Posts

blank

Novel Mangrove-Derived Streptomyces Reveals Biosynthetic Potential

September 5, 2025
CRISPR-Cas9 Techniques for Editing Non-Model Insects

CRISPR-Cas9 Techniques for Editing Non-Model Insects

September 5, 2025

Rapid Brain Growth Could Unlock How Humans and Marmosets Learn to Talk

September 4, 2025

Indigenous AMF Boosts Sustainable Cassava Farming in Thailand

September 4, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    149 shares
    Share 60 Tweet 37
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    142 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    115 shares
    Share 46 Tweet 29
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    61 shares
    Share 24 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Viral Mimicry and Mitochondrial Signals Fuel Cancer

Gestational Diabetes Thresholds Impact Infant Growth, Development

ACE2 Decoy Receptor Battles Mutant SARS-CoV-2 Variants

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.